iwNHL 2018 day 1 highlights: T-cells, biomarkers & personalized medicine

iwNHL 2018 day 1 highlights: T-cells, biomarkers & personalized medicine

VJHemOnc

1 year
61 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
The International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2018 meeting held in Nice, France, presented an array of exciting new data in NHL. Here, John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci, of Barts Cancer Institute, London, UK, discusses the highlights of day 1 of the meeting with Stephen Ansell, MD, PhD, of the Mayo Clinic, Rochester, MI, and Catherine Bollard, MBChB, MD, FRACP, FRCPA, from the Children's National Health System, Washington, DC. Some of the topics explored by the experts include enhancing T-cell response, expediting our knowledge of biomarkers, and the development of new combination regimens to target different populations of malignant cells.
Up Next Autoplay
Comparative Outcomes of Relapsed Follicular Lymphoma Patients #ASH19 @ClevelandClinic
Comparative Outcomes of Relapsed Follicular Lymphoma Patients #ASH19 @ClevelandClinic
Category: Non-Hodgkin Lymphoma
26 Views
ash 4 weeks
Analysis of Brentuximab Vedotin Plus  CHP (A+CHP) #ASH19 @OfficialUoM
Analysis of Brentuximab Vedotin Plus CHP (A+CHP) #ASH19 @OfficialUoM
Category: Non-Hodgkin Lymphoma
5 Views
ash 1 month
Follow-Up in Relapsed/Refractory MCL #ASH19
Follow-Up in Relapsed/Refractory MCL #ASH19
Category: Non-Hodgkin Lymphoma
20 Views
ash 1 month
Dose Optimization Portion of the Phase 2 PRIMO Study in Relapsed or Refractory PTCL #ASH19 @sloan_kettering
Dose Optimization Portion of the Phase 2 PRIMO Study in Relapsed or Refractory PTCL #ASH19 @sloan_kettering
Category: Non-Hodgkin Lymphoma
31 Views
ash 1 month
KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy #ASH19
KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy #ASH19
Category: Non-Hodgkin Lymphoma
4 Views
ash 1 month
Lymphopenia: How This Affects Clinicians and Treatment Today @CleClinicNews
Lymphopenia: How This Affects Clinicians and Treatment Today @CleClinicNews
Category: Non-Hodgkin Lymphoma
7 Views
Cancer-News 1 month
Immune Status, Inflammation Can Predict Mortality @CleClinicNews @CleClinicMD
Immune Status, Inflammation Can Predict Mortality @CleClinicNews @CleClinicMD
Category: Non-Hodgkin Lymphoma
3 Views
Cancer-News 1 month
Update on Phase I REGN1979 #ASH19 #ASH @RutgersCancer
Update on Phase I REGN1979 #ASH19 #ASH @RutgersCancer
Category: Non-Hodgkin Lymphoma
10 Views
ash 1 month
Epizyme Presents Updated Phase 2 Data at the 2019 ASH Annual Meeting Supporting Planned Tazemetostat NDA Submission for Follicular Lymphoma
Epizyme Presents Updated Phase 2 Data at the 2019 ASH Annual Meeting Supporting Planned Tazemetostat NDA Submission for Follicular Lymphoma
Category: Non-Hodgkin Lymphoma
27 Views
Cancer-News 1 month
Moleculin Announces Positive Trial Data with 100% Safe Delivery of p-STAT3 Inhibitor and Efficacy in Majority of Patients
Moleculin Announces Positive Trial Data with 100% Safe Delivery of p-STAT3 Inhibitor and Efficacy in Majority of Patients
Category: Non-Hodgkin Lymphoma
6 Views
Cancer-News 2 months